Evaluation of the role of EGFR exon 19 747-750 deletion mutation and plasma amino acid profile in the development of lung cancer
- PMID: 39367097
- DOI: 10.1007/s11033-024-09941-4
Evaluation of the role of EGFR exon 19 747-750 deletion mutation and plasma amino acid profile in the development of lung cancer
Abstract
Background: Lung cancer (LC) is the most common form of cancer in the world. Of the proteins involved in cell differentiation and proliferation, the epidermal growth factor receptor (EGFR) is among the most significant. Amino acids play a crucial role in cell physiology as metabolic regulators. The benefits of liquid biopsies are their non-invasive nature, ease of collection, and ability to depict the entire tumor's status. The present study is designed to detect the relation between the EGFR exon 19 747-750 deletion mutation and lung cancer and investigate the patterns of alterations of plasma-free amino acids (PFAA) in lung cancer patients of different histopathological types and stages as biomarkers for early detection of lung cancer.
Methods: The study sample comprised 60 lung cancer patients and 60 age- and sex-matched healthy individuals as the control group. Polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) were used to examine the EGFR exon 19 747-750 deletion mutation, and an AA analyzer was used to quantify the plasma free amino acid (PFAA) profile.
Results: Compared with controls, LC patients had significantly higher levels of three AAs and significantly lower levels of fifteen AAs. Thirteen AAs varied significantly between stages I and II. In the lung cancer group, the percentage of cases of mutant EGFR exon-19 deletion increased to 30% from 13.3% in the control group. The histological forms of lung cancer did not significantly differ in this rise. Valine and citrulline plasma levels were substantially greater in the mutant than in the wild-type. Lysine, histidine, and methionine were the independent predictors of the LC group in multivariate analysis.
Conclusion: Lung cancer development is influenced by the EGFR exon 19 747-750 deletion mutation, and the prognosis and early prediction of lung cancer are greatly affected by the amino acid profile concentrations.
Keywords: Amino acids; EGFR; Liquid biopsy; Lung cancer.
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.Cancer Rep (Hoboken). 2019 Aug;2(4):e1159. doi: 10.1002/cnr2.1159. Epub 2019 Feb 3. Cancer Rep (Hoboken). 2019. PMID: 32721094 Free PMC article.
-
Non-invasive detection of EGFR deletion at exon 19 in non-small cell lung cancer by real time diagnostic.Clin Lab. 2014;60(9):1517-26. doi: 10.7754/clin.lab.2014.140106. Clin Lab. 2014. PMID: 25291948
-
Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping.J Exp Clin Cancer Res. 2013 Aug 9;32(1):50. doi: 10.1186/1756-9966-32-50. J Exp Clin Cancer Res. 2013. PMID: 23927790 Free PMC article.
-
Molecular profiling and utility of cell-free DNA in nonsmall carcinoma of the lung: Study in a tertiary care hospital.J Cancer Res Ther. 2021 Oct-Dec;17(6):1389-1396. doi: 10.4103/jcrt.JCRT_99_20. J Cancer Res Ther. 2021. PMID: 34916369
-
EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.Am J Clin Oncol. 2018 Apr;41(4):385-390. doi: 10.1097/COC.0000000000000282. Am J Clin Oncol. 2018. PMID: 26967328
Cited by
-
Correlation analysis on epidermal growth factor receptor (EGFR) mutations and clinicopathological characteristics in lung adenocarcinomas.Front Oncol. 2025 Mar 20;15:1519150. doi: 10.3389/fonc.2025.1519150. eCollection 2025. Front Oncol. 2025. PMID: 40182027 Free PMC article.
References
-
- Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A (2021) Epidemiology of lung cancer. Contem Oncol (Poznan, Poland) 25:45–52
-
- Khodabakhshi Z, Mostafaei S, Arabi H, Oveisi M, Shiri I, Zaidi H (2021) Non-small cell lung carcinoma histopathological subtype phenotyping using high-dimensional multinomial multiclass CT radiomics signature. Comput Biol Med 136:104752 - DOI
-
- Chen P, Liu Y, Wen Y, Zhou C (2022) Non-small cell lung cancer in China. Cancer Commun (Lond, Eng) 42:937–970 - DOI
-
- Li W, Liu JB, Hou LK, Yu F, Zhang J, Wu W, Tang XM, Sun F, Lu HM, Deng J, Bai J, Li J, Wu CY, Lin QL, Lv ZW, Wang GR, Jiang GX, Ma YS, Fu D (2022) Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer 21:25 - DOI
-
- Casagrande GMS, Silva MO, Reis RM, Leal LF (2023) Liquid biopsy for lung cancer: up-to-date and perspectives for screening programs. Int J Mol Sci 24:25055 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous